Total Payments
$34,839
2024 Payments
$342.08
Companies
16
Transactions
62
Medicare Patients
701
Medicare Billing
$111,134
Payment Breakdown by Category
Consulting$26,504 (76.1%)
Food & Beverage$3,002 (8.6%)
Travel$2,874 (8.2%)
Other$2,460 (7.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $26,504 | 11 | 76.1% |
| Food and Beverage | $3,002 | 40 | 8.6% |
| Travel and Lodging | $2,874 | 10 | 8.2% |
| Honoraria | $2,460 | 1 | 7.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $8,296 | 5 | $0 (2023) |
| TESARO, Inc. | $7,623 | 11 | $0 (2019) |
| Aadi Bioscience, Inc. | $6,017 | 8 | $0 (2024) |
| Janssen Products, LP | $3,621 | 9 | $0 (2017) |
| Clovis Oncology, Inc. | $3,602 | 13 | $0 (2022) |
| Amgen Inc. | $2,596 | 2 | $0 (2021) |
| Eisai Inc. | $1,950 | 1 | $0 (2021) |
| Intuitive Surgical, Inc. | $241.41 | 2 | $0 (2019) |
| ABBVIE INC. | $180.85 | 2 | $0 (2024) |
| Stryker Corporation | $166.56 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $342.08 | 4 | ABBVIE INC. ($180.85) |
| 2023 | $11,269 | 10 | GlaxoSmithKline, LLC. ($8,200) |
| 2022 | $3,134 | 4 | Aadi Bioscience, Inc. ($3,097) |
| 2021 | $4,546 | 3 | Amgen Inc. ($2,596) |
| 2020 | $164.39 | 2 | GlaxoSmithKline, LLC. ($95.58) |
| 2019 | $8,087 | 14 | TESARO, Inc. ($7,482) |
| 2018 | $3,629 | 14 | Clovis Oncology, Inc. ($3,258) |
| 2017 | $3,668 | 11 | Janssen Products, LP ($3,621) |
All Payment Transactions
62 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/16/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $147.05 | General |
| Category: ONCOLOGY | ||||||
| 03/17/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $33.80 | General |
| Category: ONCOLOGY | ||||||
| 03/16/2024 | Aadi Bioscience, Inc. | Fyarro (Drug) | Food and Beverage | In-kind items and services | $34.07 | General |
| Category: Cancer | ||||||
| 03/07/2024 | Ethicon US, LLC | STRATAFIX (Device), ETHICON, Enseal | Food and Beverage | In-kind items and services | $127.16 | General |
| Category: Wound Closure | ||||||
| 12/21/2023 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: ONCOLOGY | ||||||
| 10/11/2023 | Stryker Corporation | SPY-PHI SYSTEM (Device) | Food and Beverage | In-kind items and services | $166.56 | General |
| Category: ENDOSCOPY | ||||||
| 09/19/2023 | Ethicon US, LLC | Enseal (Device), Harmonic, EVARREST | Food and Beverage | In-kind items and services | $15.99 | General |
| Category: Energy | ||||||
| 06/03/2023 | Aadi Bioscience, Inc. | Fyarro (Drug) | Food and Beverage | In-kind items and services | $184.27 | General |
| Category: Cancer | ||||||
| 06/03/2023 | Aadi Bioscience, Inc. | Fyarro (Drug) | Food and Beverage | In-kind items and services | $173.40 | General |
| Category: Cancer | ||||||
| 05/02/2023 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| Category: ONCOLOGY | ||||||
| 03/23/2023 | Aadi Bioscience, Inc. | Fyarro (Drug) | Consulting Fee | Cash or cash equivalent | $2,397.50 | General |
| Category: Cancer | ||||||
| 03/23/2023 | Aadi Bioscience, Inc. | Fyarro (Drug) | Food and Beverage | In-kind items and services | $131.00 | General |
| Category: Cancer | ||||||
| 01/10/2023 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: ONCOLOGY | ||||||
| 01/03/2023 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: ONCOLOGY | ||||||
| 10/25/2022 | Aadi Bioscience, Inc. | FYARRO (Drug) | Honoraria | Cash or cash equivalent | $2,460.00 | General |
| Category: IMMUNOSUPPRESSANT | ||||||
| 10/25/2022 | Aadi Bioscience, Inc. | FYARRO (Drug) | Travel and Lodging | In-kind items and services | $530.21 | General |
| Category: IMMUNOSUPPRESSANT | ||||||
| 10/25/2022 | Aadi Bioscience, Inc. | FYARRO (Drug) | Food and Beverage | In-kind items and services | $106.70 | General |
| Category: IMMUNOSUPPRESSANT | ||||||
| 03/19/2022 | Clovis Oncology, Inc. | Rubraca (Drug) | Food and Beverage | In-kind items and services | $37.37 | General |
| Category: Oncology | ||||||
| 08/19/2021 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| Category: Oncology | ||||||
| 01/25/2021 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $1,947.00 | General |
| 01/25/2021 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $649.00 | General |
| 02/19/2020 | Clovis Oncology, Inc. | Rubraca (Drug) | Food and Beverage | In-kind items and services | $68.81 | General |
| Category: Oncology | ||||||
| 02/07/2020 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $95.58 | General |
| Category: ONCOLOGY | ||||||
| 12/28/2019 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $63.98 | General |
| Category: SURGERY | ||||||
| 11/26/2019 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Travel and Lodging | In-kind items and services | $177.43 | General |
| Category: SURGERY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 180 | 301 | $138,441 | $31,971 |
| 2022 | 5 | 199 | 342 | $139,951 | $34,545 |
| 2021 | 5 | 187 | 301 | $107,846 | $29,819 |
| 2020 | 5 | 135 | 214 | $60,443 | $14,799 |
Total Patients
701
Total Services
1,158
Medicare Billing
$111,134
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 78 | 165 | $88,317 | $18,345 | 20.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 43 | 43 | $24,590 | $5,997 | 24.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 44 | 55 | $14,550 | $4,007 | 27.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 15 | 38 | $10,984 | $3,621 | 33.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 78 | 154 | $79,065 | $17,119 | 21.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 42 | 42 | $22,696 | $6,238 | 27.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 52 | 82 | $20,824 | $5,918 | 28.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 12 | 40 | $11,320 | $3,322 | 29.3% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 15 | 24 | $6,046 | $1,947 | 32.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 44 | 94 | $46,614 | $11,091 | 23.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 60 | 93 | $22,704 | $7,430 | 32.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 42 | 42 | $21,912 | $6,013 | 27.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 26 | 44 | $10,792 | $3,636 | 33.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 15 | 28 | $5,824 | $1,650 | 28.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 56 | 106 | $25,031 | $6,314 | 25.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 23 | 32 | $15,257 | $2,953 | 19.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 19 | 19 | $9,550 | $2,666 | 27.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 21 | 41 | $8,187 | $2,268 | 27.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 16 | 16 | $2,418 | $597.78 | 24.7% |
About Dr. Pamela Soliman, M.D
Dr. Pamela Soliman, M.D is a Gynecologic Oncology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1740367887.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Pamela Soliman, M.D has received a total of $34,839 in payments from pharmaceutical and medical device companies, with $342.08 received in 2024. These payments were reported across 62 transactions from 16 companies. The most common payment nature is "Consulting Fee" ($26,504).
As a Medicare-enrolled provider, Soliman has provided services to 701 Medicare beneficiaries, totaling 1,158 services with total Medicare billing of $111,134. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Gynecologic Oncology
- Location Houston, TX
- Active Since 11/01/2006
- Last Updated 08/30/2018
- Taxonomy Code 207VX0201X
- Entity Type Individual
- NPI Number 1740367887
Products in Payments
- ZEJULA (Drug) $10,118
- JEMPERLI (Biological) $5,800
- YONDELIS (Drug) $3,621
- Rubraca (Drug) $3,602
- FYARRO (Drug) $3,097
- Fyarro (Drug) $2,920
- Lenvima (Drug) $1,950
- Da Vinci Surgical System (Device) $241.41
- ELAHERE (Drug) $180.85
- SPY-PHI SYSTEM (Device) $166.56
- STRATAFIX (Device) $127.16
- Avastin (Biological) $126.78
- TISSEEL (Biological) $110.14
- Uterine Manipulators & Injectors (Device) $77.57
- KEYTRUDA (Biological) $36.43
- Surgical Care - Tisseel (Biological) $27.08
- AirSeal (Device) $25.61
- Enseal (Device) $15.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gynecologic Oncology Doctors in Houston
Robert Coleman, M.d, M.D
Gynecologic Oncology — Payments: $839,472
Gynecologic Oncology $839,472
Maurie Markman, M.d, M.D
Gynecologic Oncology — Payments: $479,163
Gynecologic Oncology $479,163
Dr. Aparna Kamat, M.d, M.D
Gynecologic Oncology — Payments: $234,318
Gynecologic Oncology $234,318
Anil Sood, M.d, M.D
Gynecologic Oncology — Payments: $70,682
Gynecologic Oncology $70,682
Gordon Mills, Md, Phd, MD, PHD
Gynecologic Oncology — Payments: $41,586
Gynecologic Oncology $41,586
Alpa Nick, Md, MD
Gynecologic Oncology — Payments: $40,612
Gynecologic Oncology $40,612